Literature DB >> 17760875

Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence.

Lys Adriana Braga-Silva1, André Luis Souza dos Santos, Maristela Barbosa Portela, Thaïs Souto-Padrón, Rosangela Maria de Araújo Soares.   

Abstract

Candida albicans is an opportunistic pathogen that is of growing medical importance because it causes superficial, mucosal and systemic infections in susceptible individuals. Here, the effect of suramin, a polysulfonated naphthylurea derivative, on C. albicans development and virulence was evaluated. Firstly, it was demonstrated that suramin (500 microM) arrested its growth, showing a fungicidal action dependent on cell number. Suramin treatment caused profound changes in the yeast ultrastructure as shown by transmission electron microscopy. The more important changes were the enlargement of the fungi cytoplasmic vacuoles, the appearance of yeasts with an empty cytoplasm resembling ghost cells and a reduction in cell wall thickness. Suramin also blocked the transformation of yeast cells to the germ-tube and the interaction between C. albicans and epithelial cells. In order to ascertain that the action of suramin on C. albicans growth is a general feature instead of being strain-specific, the effects of suramin on 14 oral clinical strains isolated from healthy children and HIV-positive infants were analyzed. Interestingly, the strains of C. albicans isolated from HIV-positive patients were more resistant to suramin than strains isolated from healthy patients. Altogether, the results produced here show that suramin interfered with essential fungal processes, such as growth, differentiation and interaction with host cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760875     DOI: 10.1111/j.1574-695X.2007.00321.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  3 in total

1.  The trypanocidal drug suramin and other trypan blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site.

Authors:  Hugh P Morgan; Iain W McNae; Matthew W Nowicki; Wenhe Zhong; Paul A M Michels; Douglas S Auld; Linda A Fothergill-Gilmore; Malcolm D Walkinshaw
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

2.  HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2010-02-26

3.  Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans-In Silico, In Vitro and In Vivo Approaches.

Authors:  André L S Santos; Lys A Braga-Silva; Diego S Gonçalves; Lívia S Ramos; Simone S C Oliveira; Lucieri O P Souza; Vanessa S Oliveira; Roberto D Lins; Marcia R Pinto; Julian E Muñoz; Carlos P Taborda; Marta H Branquinha
Journal:  J Fungi (Basel)       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.